Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: Impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy

Hypertension Research

Volumn 36, Issue 6, 2013, Pages 550-558

  Rabkin, Simon W ^a   Langer, Anatoly ^b   Ur, Ehud ^a   Calciu, Cristina Dana ^c   Leiter, Lawrence A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c PFIZER INC   (United States)

Author keywords

atorvastatin; CRP; interleukin 18; MCP 1; serum amyloid alpha

Indexed keywords

AMYLOID ALPHA; AMYLOID PROTEIN; ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE RESPONSE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CANADA; CHEMOKINE CCL2; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INTERLEUKIN-18; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDE FRAGMENTS; RISK ASSESSMENT; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84877259002     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.214     Document Type: Article

References (64)

1. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593. (Pubitemid 44465680)
2. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007; 8: 145-153. (Pubitemid 47502964)
3. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007; 39: 707-709. (Pubitemid 350099816)
4. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 120-127. (Pubitemid 36547812)
5. Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, Herrington DM. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens 2010; 25: 73-79.
6. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874. (Pubitemid 36019640)
7. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med 2004; 36: 98-118. (Pubitemid 38510016)
8. Suchanek H, Mysliwska J, Siebert J, Wieckiewicz J, Hak L, Szyndler K, Kartanowicz D. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw 2005; 16: 177-185. (Pubitemid 46638747)
9. Rabkin SW. The role of Interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009; 6: 192-199.
10. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242. (Pubitemid 29056365)
11. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
12. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397. (Pubitemid 38419992)
13. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008; 359: 2195-2207.
14. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 266-274. (Pubitemid 46143039)
15. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44: 1812-1818. (Pubitemid 39424080)
16. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301-307. (Pubitemid 41579281)
17. Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, Koenig W. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26: 2147-2152. (Pubitemid 44253801)
18. Hognestad A, Endresen K, Wergeland R, Mellembakken JR, Mollnes TE, Omland T, Kjekshus JK, Aukrust P, Andreassen AK. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 2005; 24: 1026-1032. (Pubitemid 41127184)
19. deLemos J, Morrow D, Sabatine M, Murphy S, Gibson C, Antman E, McCabe C, Cannon C, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-695. (Pubitemid 36222595)
20. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 1268-1273. (Pubitemid 40776620)
21. Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21-28.
22. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, Buerke M, Darius H, Lindemann S. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005; 69: 1484-1489. (Pubitemid 41743963)
23. O'Brien KD, Chait A. Serum amyloid A: the 'other' inflammatory protein. Curr Atheroscler Rep 2006; 8: 62-68. (Pubitemid 43675756)
24. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96: 2914-2919. (Pubitemid 27500090)
25. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, Timmel E, Kickinger B, Minar C, Pones M, Lalouschek W, Rumpold H, Maurer G, Wagner O, Minar E. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation 2005; 111: 2203-2209. (Pubitemid 40632436)
26. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844. (Pubitemid 28397432)
27. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE. National Heart LaBI. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732. (Pubitemid 38222891)
28. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006; 188: 450-454. (Pubitemid 44313924)
29. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene I. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30. (Pubitemid 34747437)
30. Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26: 2745-2751.
31. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G, Nishibori M. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005; 77: 400-407. (Pubitemid 40289570)
32. Leu HB, Chen JW, Wu TC, Ding YA, Lin SJ, Charng MJ. Effects of fluvastatin, an HMGCoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol 2005; 28: 423-428.
33. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, Fung JW, Cheng KK, Chan IH, Lee SW, Sanderson JE, Lam CW. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007; 93: 933-939. (Pubitemid 47122042)
34. Liu Y, Jiang H, Liu W, Shang H, Tang Y, Zhu R, Li B. Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome. Acta Cardiol 2010; 65: 285-289.
35. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008; 30: 2298-2313.
36. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J, investigators A. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007; 153: 881-888. (Pubitemid 46602154)
37. Rallidis LS, Hamodraka ES, Fountoulaki K, Moustogiannis G, Zolindaki MG, Kremastinos DT. Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Int J Cardiol 2008; 124: 271-272. (Pubitemid 351173361)
38. Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100: 222-226. (Pubitemid 47041985)
39. Han KH, Ryu J, Hong KH, Ko J, Pak YK, Kim JB, Park SW, Kim JJ. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005; 111: 1439-1447. (Pubitemid 40396811)
40. Takebayashi K, Matsumoto S, Wakabayashi S, Inukai Y, Matsutomo R, Aso Y, Inukai T. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 2005; 54: 1225-1229. (Pubitemid 41206883)
41. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 2002; 90: 942-946. (Pubitemid 35232616)
42. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-1566. (Pubitemid 37187781)
43. Horiuchi Y, Hirayama S, Soda S, Seino U, Kon M, Ueno T, Idei M, Hanyu O, Tsuda T, Ohmura H, Miida T. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 2010; 17: 722-729.
44. Ehud U, Langer A, Rabkin SW, Calciu CD, Leiter LA. Achieving cholesterol targets by individualizing starting doses of statin according to baseline LDL-C and coronary artery disease risk category: The CanACTFAST Study. Can J Cardiol 2010; 26: 80-86.
45. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis Jr JF, Smith Jr S, Stone NJ, Taubert KA. American Heart Association Expert Panel on Population and Prevention S. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107: 645-651. (Pubitemid 36176819)
46. Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension 1994; 24: 241-248.
47. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
48. Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006; 16: 500-508. (Pubitemid 44472604)
49. Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K, Stefanadis C. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231-2238. (Pubitemid 44611032)
50. Boos CJ, Lip GY. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J Hum Hypertens 2005; 19: 511-513. (Pubitemid 40946034)
51. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 2005; 54: 2932-2938. (Pubitemid 41401089)
52. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, McGuire DK, Vega GL, Grundy S, Libby P, de Lemos JA. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 2043-2049. (Pubitemid 47312316)
53. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L, Group PS. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459. (Pubitemid 37444405)
54. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB-and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006; 281: 15099-15109. (Pubitemid 43855099)
55. Blomqvist HM, Olsson AG. Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia. Scand J Clin Lab Invest 2003; 63: 513-519. (Pubitemid 38121718)
56. Zhuo JL. Monocyte chemoattractant protein-1: a key mediator of angiotensin IIinduced target organ damage in hypertensive heart disease? J Hypertens 2004; 22: 451-454. (Pubitemid 38368474)
57. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692. (Pubitemid 39665258)
58. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534. (Pubitemid 32521959)
59. Bartolak-Suki E, Sipe JD, Fine RE, Rosene DL, Moss MB, Bartolak-Suki E, Sipe JD, Fine RE, Rosene DL, Moss MB. Serum amyloid A is present in the capillaries and microinfarcts of hypertensive monkey brain: an immunohistochemical study. Amyloid 2000; 7: 111-117. (Pubitemid 30318070)
60. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, Stefanadis C, Kallikazaros I. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 2005; 96: 252-256. (Pubitemid 40978584)
61. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 2008; 28: 142-147.
62. Vyssoulis GP, Tousoulis D, Antoniades C, Dimitrakopoulos S, Zervoudaki A, Stefanadis C. Alpha-1 microglobulin as a new inflammatory marker in newly diagnosed hypertensive patients. Am J Hypertens 2007; 20: 1016-1021. (Pubitemid 47313614)
63. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168: 721-727. (Pubitemid 351563955)
64. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19: 103-109. (Pubitemid 40220632)